اخبار و اعلانات

 آمار

تعداد نشریات282
تعداد نشریات سازمان80
تعداد شماره‌ها3,188
تعداد مقالات35,336
تعداد مشاهده مقاله51,458,569
تعداد دریافت فایل اصل مقاله91,332,019
Mahde, B. W, Abbas Hussein, A, Sahib, A. S. (1402). Preparation and in vitro Evaluation of Rasagiline Mesylate Hybrid Nanoparticles. سامانه مدیریت نشریات علمی, 78(3), 1023-1028. doi: 10.22092/ari.2022.360193.2563
B. W Mahde; A Abbas Hussein; A. S Sahib. "Preparation and in vitro Evaluation of Rasagiline Mesylate Hybrid Nanoparticles". سامانه مدیریت نشریات علمی, 78, 3, 1402, 1023-1028. doi: 10.22092/ari.2022.360193.2563
Mahde, B. W, Abbas Hussein, A, Sahib, A. S. (1402). 'Preparation and in vitro Evaluation of Rasagiline Mesylate Hybrid Nanoparticles', سامانه مدیریت نشریات علمی, 78(3), pp. 1023-1028. doi: 10.22092/ari.2022.360193.2563
Mahde, B. W, Abbas Hussein, A, Sahib, A. S. Preparation and in vitro Evaluation of Rasagiline Mesylate Hybrid Nanoparticles. سامانه مدیریت نشریات علمی, 1402; 78(3): 1023-1028. doi: 10.22092/ari.2022.360193.2563

Preparation and in vitro Evaluation of Rasagiline Mesylate Hybrid Nanoparticles

Archives of Razi Institute
مقاله 30، دوره 78، شماره 3، مرداد و شهریور 2023، صفحه 1023-1028    اصل مقاله (523.67 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.360193.2563
نویسندگان
B. W Mahde* 1، 2؛ A Abbas Hussein3؛ A. S Sahib4
1College of Pharmacy, University of Al-Qadisiyah, Al-Qadisiyah, Iraq
2College of Pharmacy, University of Baghdad, Baghdad, Iraq
3Baghdad College of Medical Sciences, Baghdad, Iraq
4Al-Mustaqbal University College, Babylon, Iraq
چکیده
Rasagiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B) that is effective in the treatment of Parkinson’s disease (PD). It had antioxidant and anti-apoptotic activity in experimental models. Moreover, it has low permeability and its oral bioavailability is weak and highly variable due to extensive first-pass hepatic metabolism (35%). This study aimed to formulate rasagiline mesylate (RM) as a lipid-polymer hybrid nanoparticle in order to enhance its permeation and increase its chance to be absorbed by lymphatic circulation to avoid metabolism and control its release. Successful formulation (PCL-2) was reached by the nanoprecipitation method using polycaprolactone with RM in the organic phase and lecithin in the aqueous phase DSPE-PEG. The lipid:polymer ratio of 24% and DSPE: lecithin of 50% resulted in stable nanoparticles having a particle size of 132±4.58 nm, polydispersity index of 0.273±0.02, zeta potential of -25.6±3.3, entrapment efficiency of 46±3.9%, and drug loading of 51.93±6.5. Results showed that the diffusion was more effective on the release profile than the degradation and resulted in a Fickian diffusion mechanism.
کلیدواژه‌ها
Nanoparticles؛ Parkinson's disease؛ Propargylamine؛ Rasagiline
سایر فایل های مرتبط با مقاله
مراجع
  1. Finberg JP, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol. 2016;7:340.
  2. Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm. 2016;123(2):91-106.
  3. Mueller BK, Schmidt M, Barlow E, Leddy M, Hsieh CM, Bardwell P. AbbVie Deutschland GmbH and Co KG, AbbVie Inc. Antibodies against the RGM A protein and uses thereof. United States patent US. 2015(24).
  4. Szökő É, Tábi T, Riederer P, Vécsei L, Magyar K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease. J Neural Transm. 2018;125(11):1735-49.
  5. Meier-Davis SR, Dines K, Arjmand FM, Hamlin R, Huang B, Wen J, et al. Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo. Cutan Ocul Toxicol. 2012;31(4):312-7.
  6. Anderson GD, Chan L-N. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet. 2016;55(11):1353-68.
  7. Hiemke C, Bergemann N, Clement H, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(01/02):9-62.
  8. Rijswick V, Quesada, Van Os S. Bioequivalence between generic rasagiline (as tartrate) and rasagiline (as mesylate). J Bioequiv. 2016;2:201-6
  9. KrishnaSailaja A, Siddiqua A. An overall review on polymeric nanoparticles. Int J Pharm Pharm Sci. 2017:21-8.
  10. Castro KCd, Costa JM, Campos MGN. Drug-loaded polymeric nanoparticles: a review. International J Polym Mater Polym Biomaterials. 2022;71(1):1-13.
  1. Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv. 2012;2012.
  2. Mandal B, Bhattacharjee H, Mittal N, Sah H, Balabathula P, Thoma LA, et al. Core–shell-type lipid–polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine: NBM. 2013;9(4):474-91.
  3. Jadhav P, Yadav A. Formulation, optimization, and in vitro evaluation of polymeric nanosuspension of flurbiprofen. Asian J Pharm Clin Res. 2019;12(11):183-91.
  4. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.
  5. Thiyagarajan A, Saravanabhavan S, Thangarasu V. Preparation and biopharmaceutical evaluation of novel polymeric nanoparticles containing etoposide for targeting cancer cells. Turk J Pharm Sc. 2019;16(2):132.
  6. Hua S. Comparison of in vitro dialysis release methods of loperamide-encapsulated liposomal gel for topical drug delivery. Int J Nanomedicine. 2014;9:735.
  7. Omer ME, Halwani M, Alenazi RM, Alharbi O, Aljihani S, Massadeh S, et al. Novel Self-Assembled Polycaprolactone–Lipid Hybrid Nanoparticles Enhance the Antibacterial Activity of Ciprofloxacin. SLAS Technol. 2020;25(6):598-607.
  8. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28-51.
  9. Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68(3):701-87.
  10. D’Souza S. A review of in vitro drug release test methods for nano-sized dosage forms. Adv Pharmacol Sci. 2014;2014.
آمار
تعداد مشاهده مقاله: 2,710
تعداد دریافت فایل اصل مقاله: 7,417


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب